-
公开(公告)号：US07465705B2
公开(公告)日：2008-12-16
申请号：US11055163
申请日：2005-02-10
Applicant: Daniel H. S. Lee , R. Blake Pepinsky , Weiwei Li , Jane K. Relton , Dane S. Worley , Stephen M. Strittmatter , Dinah W. Y. Sah , Sylvia A. Rabacchi
Inventor： Daniel H. S. Lee , R. Blake Pepinsky , Weiwei Li , Jane K. Relton , Dane S. Worley , Stephen M. Strittmatter , Dinah W. Y. Sah , Sylvia A. Rabacchi
CPC classification number: C07K14/705 , A61K2039/505 , C07K16/2863 , C07K2317/21 , C07K2317/34 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2319/00 , C07K2319/30 , Y10S530/809
Abstract: Disclosed are immunogenic Nogo receptor-1 polypeptides, Nogo receptor-1 antibodies, antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof and nucleic acids encoding the same. Also disclosed are compositions comprising, and methods for making and using, such Nogo receptor antibodies, antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof and nucleic acids encoding the same.
Abstract translation: 公开了免疫原性Nogo受体-1多肽，Nogo受体-1抗体，其抗原结合片段，可溶性Nogo受体及其融合蛋白和编码其的核酸。 还公开了包含这样的Nogo受体抗体，其抗原结合片段，可溶性Nogo受体及其融合蛋白以及编码其的核酸的制备和使用方法。
-
公开(公告)号：US07456255B2
公开(公告)日：2008-11-25
申请号：US11544013
申请日：2006-10-06
Applicant: Stephen Strittmatter , Richard L. Cate , Dinah W. Y. Sah
Inventor： Stephen Strittmatter , Richard L. Cate , Dinah W. Y. Sah
CPC classification number: C07K16/28 , C07K14/705 , G01N33/6896 , G01N33/74 , G01N2500/00
Abstract: The invention relates generally to genes that encode proteins that inhibit axonal growth. The invention relates specifically to genes encoding NgR protein homologs in humans and mice. The invention also includes compositions and methods for modulating the expression and activity of Nogo and the NgR proteins. Specifically, the invention includes peptides, proteins and antibodies that block Nogo-mediated inhibition of axonal extension. The compositions and methods of the invention are useful in the treatment of cranial or cerebral trauma, spinal cord injury, stroke or a demyelinating disease.
Abstract translation: 本发明一般涉及编码抑制轴突生长的蛋白质的基因。 本发明具体涉及在人和小鼠中编码NgR蛋白同源物的基因。 本发明还包括调节Nogo和NgR蛋白的表达和活性的组合物和方法。 具体地，本发明包括阻断Nogo介导的轴突延伸抑制的肽，蛋白质和抗体。 本发明的组合物和方法可用于治疗颅脑损伤或脑损伤，脊髓损伤，卒中或脱髓鞘疾病。
-
公开(公告)号：US07276580B2
公开(公告)日：2007-10-02
申请号：US10661984
申请日：2003-09-12
Applicant: Dinah W. Y. Sah , Teit E. Johansen , Anthony Rossomando
Inventor： Dinah W. Y. Sah , Teit E. Johansen , Anthony Rossomando
CPC classification number: C07K14/48 , A61K38/00 , C07K14/475
Abstract: The invention relates to neublastin neurotrophic factor polypeptides, nucleic acids encoding neublastin polypeptides, and antibodies that bind specifically to neublastin polypeptides, as well as methods of making and methods of using the same.
Abstract translation: 本发明涉及新斯的斯顿神经营养因子多肽，编码新斯的斯多肽的核酸，以及特异性结合到新斯普霉素多肽的抗体，以及其制备方法及其使用方法。
-
公开(公告)号：US06835567B1
公开(公告)日：2004-12-28
申请号：US09060409
申请日：1998-04-14
Applicant: Dinah W. Y. Sah , Heather K. Raymon
Inventor： Dinah W. Y. Sah , Heather K. Raymon
IPC: C12N500
CPC classification number: C07K14/82 , C12N5/0623 , C12N2503/00 , C12N2510/04 , C12N2740/13043 , G01N33/5058
Abstract: Conditionally-immortalized PNS progenitor cell lines are provided. Such cell lines, which may be clonal, may be used to generate neurons. The cell lines and/or differentiated cells may be used for the development of therapeutic agents to prevent and treat a variety of PNS-related diseases. The cell lines and/or differentiated cells may also be used in assays and for the general study of PNS cell development, death and abnormalities.
Abstract translation: 提供有条件永生化的PNS祖细胞系。 可以使用克隆的这种细胞系来产生神经元。 细胞系和/或分化细胞可用于开发治疗剂以预防和治疗各种PNS相关疾病。 细胞系和/或分化细胞也可用于测定和PNS细胞发育，死亡和异常的一般研究。
-
公开(公告)号：US08030456B2
公开(公告)日：2011-10-04
申请号：US12335328
申请日：2008-12-15
Applicant: Daniel H. S. Lee , R. Blake Pepinsky , Weiwei Li , Jane K. Relton , Dane S. Worley , Stephen M. Strittmatter , Dinah W. Y. Sah , Sylvia A. Rabacchi
Inventor： Daniel H. S. Lee , R. Blake Pepinsky , Weiwei Li , Jane K. Relton , Dane S. Worley , Stephen M. Strittmatter , Dinah W. Y. Sah , Sylvia A. Rabacchi
CPC classification number: C07K14/705 , A61K2039/505 , C07K16/2863 , C07K2317/21 , C07K2317/34 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2319/00 , C07K2319/30 , Y10S530/809
Abstract: Disclosed are immunogenic Nogo receptor-1 polypeptides, Nogo receptor-1 antibodies, antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof and nucleic acids encoding the same. Also disclosed are compositions comprising, and methods for making and using, such Nogo receptor antibodies, antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof and nucleic acids encoding the same.
Abstract translation: 公开了免疫原性Nogo受体-1多肽，Nogo受体-1抗体，其抗原结合片段，可溶性Nogo受体及其融合蛋白和编码其的核酸。 还公开了包含这样的Nogo受体抗体，其抗原结合片段，可溶性Nogo受体及其融合蛋白以及编码其的核酸的制备和使用方法。
-
Patent Agency Ranking
6.发明授权Methods of activating RET receptor tyrosine kinase using neurotrophic factors 有权使用神经营养因子激活RET受体酪氨酸激酶的方法公开(公告)号：US07655463B2
公开(公告)日：2010-02-02
申请号：US12029917
申请日：2008-02-12
Applicant: Dinah W. Y. Sah , Teit E. Johansen , Anthony Rossomando
Inventor： Dinah W. Y. Sah , Teit E. Johansen , Anthony Rossomando
IPC: C12N5/00 , C12N5/02 , A61K38/00 , C07K1/00 , C07K2/00 , C07K4/00 , C07K5/00 , C07K7/00 , C07K14/00 , C07K16/00 , C07K17/00
CPC classification number: C07K14/48 , A61K38/00 , C07K14/475
Abstract: The invention relates to neublastin neurotrophic factor polypeptides, nucleic acids encoding neublastin polypeptides, and antibodies that bind specifically to neublastin polypeptides, as well as methods of making and methods of using the same.
Abstract translation: 本发明涉及新斯的斯顿神经营养因子多肽，编码新斯的斯多肽的核酸，以及特异性结合到新斯普霉素多肽的抗体，以及其制备方法及其使用方法。
-
公开(公告)号：US08957038B2
公开(公告)日：2015-02-17
申请号：US13383560
申请日：2010-07-15
Applicant: Dinah W. Y. Sah , Andrei P. Guzaev , Matthew H. Adams , Pei Ge , Muthiah Manoharan , Douglas Ulen Gwost , Gregory Robert Stewart , David Kent Stiles , Brian Dale Nelson , William Frederick Kaemmerer , Don Marshall Gash
Inventor： Dinah W. Y. Sah , Andrei P. Guzaev , Matthew H. Adams , Pei Ge , Muthiah Manoharan , Douglas Ulen Gwost , Gregory Robert Stewart , David Kent Stiles , Brian Dale Nelson , William Frederick Kaemmerer , Don Marshall Gash
IPC: A61K31/70 , C07H21/02 , C07H21/04 , C12N15/113 , C12Q1/68
CPC classification number: A61K51/0491 , A61K49/04 , A61K49/06 , A61M5/007 , C12N15/113 , C12N2310/11 , C12N2310/14 , C12N2310/315 , C12N2310/321 , C12N2310/346 , C12N2310/3517 , C12N2320/10 , C12N2320/35 , C12N2310/3521
Abstract: This invention provides treatment compositions as well as systems and methods of determining and administering an effective amount of treatment for a neurological disorder. The treatment composition can contain a labeled interfering RNA (iRNA) agent capable of decreasing expression of a target RNA associated with the neurological disorder. The methods of the invention include determining an effective amount of a therapeutic composition by introducing a solution containing a tracer into the brain of a mammal. The tracing solution is monitored until a target volume of distribution at steady state distribution is substantially achieved, and the rate of delivery of the therapeutic composition is determined. The therapeutic composition can then be administered at the rate determined by use of the tracing solution.
Abstract translation: 本发明提供治疗组合物以及确定和施用有效量的神经障碍治疗的系统和方法。 治疗组合物可以含有能够降低与神经障碍相关的靶RNA表达的标记的干扰RNA（iRNA）试剂。 本发明的方法包括通过将含有示踪剂的溶液引入哺乳动物的脑中来确定治疗组合物的有效量。 监测追踪溶液，直到基本上达到稳定状态分布的目标体积分布，并确定治疗组合物的递送速率。 然后可以以通过使用追踪溶液确定的速率施用治疗组合物。
-
公开(公告)号：US20130130981A1
公开(公告)日：2013-05-23
申请号：US13603202
申请日：2012-09-04
Applicant: Dinah W. Y. Sah
Inventor： Dinah W. Y. Sah
CPC classification number: A61K38/185 , A61K31/56 , A61K45/06 , A61K47/60 , Y02A50/401 , A61K2300/00
Abstract: The invention relates to treatments of neuropathic pain, including tactile allodynia, and to treatments for reducing loss of pain sensitivity associated with neuropathy. The present treatments involve the use of neublastin (NBN) polypeptides.
-
公开(公告)号：US08217146B2
公开(公告)日：2012-07-10
申请号：US12632517
申请日：2009-12-07
Applicant: Dinah W. Y. Sah , Teit E. Johansen , Anthony Rossomando
Inventor： Dinah W. Y. Sah , Teit E. Johansen , Anthony Rossomando
IPC: C07K1/00 , C07K14/00 , C07K17/00 , A01N61/00 , A61K31/00 , A61K38/00 , A61K38/28 , A61K38/16 , A61P3/10 , A61P7/12 , A61P3/04 , A61P25/00 , A61P25/02 , A61P23/00
CPC classification number: C07K14/48 , A61K38/00 , C07K14/475
Abstract: The invention relates to neublastin neurotrophic factor polypeptides, nucleic acids encoding neublastin polypeptides, and antibodies that bind specifically to neublastin polypeptides, as well as methods of making and methods of using the same.
Abstract translation: 本发明涉及新斯的斯顿神经营养因子多肽，编码新斯的斯多肽的核酸，以及特异性结合到新斯普霉素多肽的抗体，以及其制备方法及其使用方法。
-
公开(公告)号：US20120116360A1
公开(公告)日：2012-05-10
申请号：US13383560
申请日：2010-07-15
Applicant: Dinah W. Y. Sah , Andrei P. Guzaev , Matthew H. Adams , Pei Ge , Muthiah Manoharan , Douglas Ulen Gwost , Gregory Robert Stewart , David Kent Stiles , Brian Dale Nelson , William Frederick Kaemmerer , Don Marshall Gash
Inventor： Dinah W. Y. Sah , Andrei P. Guzaev , Matthew H. Adams , Pei Ge , Muthiah Manoharan , Douglas Ulen Gwost , Gregory Robert Stewart , David Kent Stiles , Brian Dale Nelson , William Frederick Kaemmerer , Don Marshall Gash
IPC: A61M5/168 , A61K49/00 , A61M5/142 , A61K31/7088
CPC classification number: A61K51/0491 , A61K49/04 , A61K49/06 , A61M5/007 , C12N15/113 , C12N2310/11 , C12N2310/14 , C12N2310/315 , C12N2310/321 , C12N2310/346 , C12N2310/3517 , C12N2320/10 , C12N2320/35 , C12N2310/3521
Abstract: This invention provides treatment compositions as well as systems and methods of determining and administering an effective amount of treatment for a neurological disorder. The treatment composition can contain a labeled interfering RNA (iRNA) agent capable of decreasing expression of a target RNA associated with the neurological disorder. The methods of the invention include determining an effective amount of a therapeutic composition by introducing a solution containing a tracer into the brain of a mammal. The tracing solution is monitored until a target volume of distribution at steady state distribution is substantially achieved, and the rate of delivery of the therapeutic composition is determined. The therapeutic composition can then be administered at the rate determined by use of the tracing solution.
Abstract translation: 本发明提供治疗组合物以及确定和施用有效量的神经障碍治疗的系统和方法。 治疗组合物可以含有能够降低与神经障碍相关的靶RNA表达的标记的干扰RNA（iRNA）试剂。 本发明的方法包括通过将含有示踪剂的溶液引入哺乳动物的脑中来确定治疗组合物的有效量。 监测追踪溶液，直到基本上达到稳定状态分布的目标体积分布，并确定治疗组合物的递送速率。 然后可以以通过使用追踪溶液确定的速率施用治疗组合物。
-
-
-
-
-
-
-
-
-
Search Results
17
records
(took 0.025 seconds)
